Ofatumumab‐based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

Although rituximab‐based chemoimmunotherapy (CIT) has substantially improved clinical outcomes in chronic lymphocytic leukemia (CLL), only 40% to 50% of patients achieve a complete remission (CR). There remains interest in identifying new approaches to improve the effectiveness of CIT. Ofatumumab is a fully human anti‐CD20 monoclonal antibody with greater apparent single‐agent activity than rituximab in CLL patients.

[1]  Deborah A. Bowen,et al.  Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). , 2013, Blood.

[2]  M. Caligiuri,et al.  Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties , 2013, The Journal of Immunology.

[3]  H. Döhner,et al.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Connors,et al.  Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials , 2012, Leukemia & lymphoma.

[5]  W. Wierda,et al.  Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. , 2011, Blood.

[6]  T. Kipps,et al.  Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. , 2011, Blood.

[7]  T. Illidge,et al.  Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. , 2011, Blood.

[8]  M. Hallek,et al.  Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. , 2011, Blood.

[9]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[10]  E. Kimby,et al.  Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia , 2010, Medical oncology.

[11]  M. Dyer,et al.  Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[13]  M. Grever,et al.  Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T Hamblin,et al.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.

[15]  J. Byrd,et al.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia , 2007, Leukemia.

[16]  Lisa L. Smith,et al.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. , 2006, Blood.

[17]  P. Parren,et al.  The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.

[18]  G. Brittinger,et al.  Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.

[19]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Grever,et al.  Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997. , 2004 .

[21]  K. Haas,et al.  The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.

[22]  J. Byrd,et al.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). , 2003, Blood.

[23]  T. Barbui,et al.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.

[24]  A. López-Guillermo,et al.  Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. , 2001, Blood.

[25]  P. Feugier,et al.  Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. , 2001, Blood.

[26]  M. Grever,et al.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Kantarjian,et al.  Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[29]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[30]  W. Hiddemann,et al.  Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.